Traverse Biotech has been awarded a Phase I SBIR grant from the National Cancer Institute to develop targeted immunotherapy for selected solid tumors

Traverse Biotech, Inc announced today that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).